# A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy

> **NCT01488877** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 6 (actual)

## Conditions studied

- Type 2 Diabetic Nephropathy

## Interventions

- **DRUG:** PF-03882845
- **DRUG:** PF-03882845
- **DRUG:** PF-03882845
- **DRUG:** Spironolactone
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT01488877
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-01
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2013-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01488877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01488877, "A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01488877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*